

## JAGSONPAL PHARMACEUTICALS LIMITED

Corporate Office: Nimai Tower, 3<sup>rd</sup> Floor, Plot No. 412-415, Phase-IV, Udyog Vihar, Gurugram -122015, Haryana (India)

February 27, 2025

Listing Compliance Monitoring Team  
BSE Ltd,  
Phiroze Jeejeebhoy Towers,  
Dalal Street  
Mumbai-400 001  
Scrip Code: 507789

Sub: **Clarification in reference to the Corporate Announcement filed under Regulation 30 of SEBI (LODR) Regulations, 2015 dated February 21, 2025**

Dear Sir/Madam,

With reference to email dated February 22, 2025. We wish to submit as follows:

**Query:**

**Additional Details Required under SEBI Circular dated November 11, 2024, for Corporate Announcement filed under Regulation 30 of SEBI (LODR) Regulations, 2015. - Material Event is not disclosed to the Exchange within 24 Hours. (submit reason for delay)**

**Response:**

Jagsonpal Pharmaceuticals Limited has a **focus on Indian pharmaceutical market** with a proven track record of over four decades. The Company is in **formulations**, focusing on Gynaecology, Orthopaedics, Dermatology and Child-care segments, **all of which are sold in India**, supported by extensive pan-India presence and an experienced sales team of over 900 professionals.

USFDA's warning letter is regarding Tolnaftate, an over the counter (OTC) API produced by the company in a contractual site. Tolnaftate business to United States is **below the materiality threshold limit as defined under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**. Further, Jagsonpal has no other business with US. Hence, the disclosure was not submitted basis the defined materiality criteria.

We request you to kindly take the above clarification on the record.

For Jagsonpal Pharmaceuticals Limited

**Abhishek Joshi**  
Company Secretary and Compliance Officer